LENZ Therapeutics
LENZ
58 hedge funds and large institutions have $432M invested in LENZ Therapeutics in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 11 closing their positions.
127% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.3% less ownership
Funds ownership: 8.85% → 8.54% (-0.3%)
3% less funds holding
Funds holding: 60 → 58 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
27% less capital invested
Capital invested by funds: $587M → $432M (-$156M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.15M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.97M |
| 3 |
Morgan Stanley
New York
|
+$3.37M |
| 4 |
BlackRock
New York
|
+$3.11M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$15.2M |
| 2 |
DM
Deerfield Management
New York
|
-$14.9M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.47M |
| 4 |
Millennium Management
New York
|
-$4.91M |
| 5 |
Jennison Associates
New York
|
-$4.86M |
LENZ Hedge Fund Activity: Q4 2021 in Review
58 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q4 2021, worth a combined $432M — down 27% from $587M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LENZ and 9 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 25 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $8.15M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $15.2M sold.
- 58 institutional investors held LENZ Therapeutics (LENZ) as of Q4 2021, down from 60 in Q3 2021.
- Funds reported $432M of LENZ Therapeutics stock for Q4 2021, down 27% quarter-over-quarter.
- 9 funds opened new LENZ Therapeutics positions in Q4 2021 and 11 closed out, a net change of -2 holders.
- The largest LENZ Therapeutics buyer in Q4 2021 was EcoR1 Capital, an estimated $8.15M added.
- The largest LENZ Therapeutics seller in Q4 2021 was Janus Henderson Group, an estimated $15.2M sold.
Based on aggregated 13F filings for Q4 2021.